Non-Hodgkin lymphoma is not a single disease but a broad family of blood cancers that arise from B or T lymphocytes, each with different behaviors and treatment needs. Some subtypes are highly aggressive and require urgent treatment, while others grow slowly and may not need treatment for years.
What's actually going on in research
CAR-T cell therapy — where a patient's own immune cells are engineered to attack lymphoma — has become a standard option for several aggressive subtypes after two prior treatments, and is now being tested much earlier in the course of disease. Bispecific antibodies that recruit the immune system without requiring cell manufacturing are showing strong response rates and are more accessible than CAR-T. Small-molecule drugs targeting the BTK pathway and BCL-2 protein continue to expand treatment options for both indolent and aggressive subtypes.
CAR-T cell therapy
Engineering a patient's own T-cells to recognize and kill lymphoma cells has become a standard approach for relapsed aggressive lymphoma, and trials are now testing it as earlier therapy.
Bispecific antibodies
These off-the-shelf drugs simultaneously bind a lymphoma protein and a T-cell protein, forcing the immune system to attack the tumor without needing individualized cell manufacturing.
BTK and BCL-2 inhibitors
Oral drugs that block cell-survival signals — BTK inhibitors and BCL-2 inhibitors like venetoclax — are transforming treatment for slower-growing subtypes and being tested in combinations for aggressive disease.
What to know before you search
Eligibility depends on lymphoma subtype, B-cell vs. T-cell origin, prior therapies, performance status, and specific molecular markers like CD19 and BCL-2 expression.
What types of trials are currently open
- Treatment trials — Testing new drug combinations, immunotherapies, or cell therapies in various Non-Hodgkin lymphoma subtypes.
- CAR-T trials — Evaluating engineered T-cell therapies in earlier lines of treatment or new lymphoma subtypes.
- Watch-and-wait trials — Studying when to start treatment in indolent lymphomas and whether early intervention improves survival.
- Transplant trials — Comparing stem cell transplant strategies and conditioning regimens for high-risk patients.
- Supportive care trials — Testing management of infections and other treatment complications.
Recently added Non-hodgkin Lymphoma trials
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
This is a single-arm, prospective, phase 2 clinical trial evaluating the improvement of survival outcomes of blinatumomab combined with chemotherapy as a full-course treatment regimen in patients with newly diagnosed Philadelphia chromosome-negative (Ph-negative) B-cell precursor acute lymphoblastic leukemia (B-ALL). The study adopts a "reduced-dose chemotherapy + full-course immunotherapy" strategy: induction therapy with reduced-dose chemotherapy combined with blinatumomab to improve remission rate and tolerability; consolidation therapy with alternating Hyper-CVAD (A/B) regimen，blinatumomab and sequential CD19-directed CAR-T therapy to deepen minimal residual disease (MRD) clearance; allogeneic hematopoietic stem cell transplantation (allo-HSCT) for some patients (e.g., KMT2A rearrangement, TP53 mutation, persistent MRD positivity, MRD recurrence); and no maintenance therapy. The primary endpoint is 2-year relapse-free survival (RFS). Secondary endpoints include 2-year overall survival (OS), the proportion and time to achieve complete response (CRc), and the proportion and time to achieve minimal residual disease (MRD) negativity. The trial plans to enroll 101 patients aged 15-65 years to demonstrate improved survival outcomes compared with historical controls .
Find Non-hodgkin Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.